论文部分内容阅读
目的:观察阿托伐它汀对血脂正常的冠心病患者的治疗意义。方法:102例血脂正常的冠心病患者随机分为阿托伐它汀组(62例)及对照组(40例)。两组均除外肝肾功能异常及其他心脏疾患,其中合并高血压病31例,合并糖尿病14例。在冠心病常规治疗基础上,严格控制血压及血糖水平,治疗组口服阿托伐它汀10~20 mg,1次/d,治疗6~12个月;对照组不给予阿托伐它汀,其他治疗相同。治疗前后观察血尿常规、血脂及肝肾功能变化,并行冠状动脉造影检查。结果:观察组有18.3%的冠状动脉病变进展,对照组有49.4%,观察组11.3%患者病情恶化,明显少于对照组的62.5%(P<0.05)。病变减轻及消失情况虽好于对照组,但无统计学意义。而病变好转数(病变减轻+病变消失)观察组显著多于对照组(P<0.05)。结论:对血脂正常的冠心病患者,阿托伐它汀的治疗能明显减低近期冠状动脉病变进展及病情恶化。
Objective: To observe the therapeutic effect of atorvastatin on patients with coronary heart disease with normal blood lipids. Methods: A total of 102 patients with coronary heart disease were randomly divided into atorvastatin group (n = 62) and control group (n = 40). Both groups except liver and kidney dysfunction and other heart disease, including 31 cases of hypertension, with diabetes in 14 cases. In the routine treatment of coronary heart disease, based on strict control of blood pressure and blood glucose levels, the treatment group oral atorvastatin 10 ~ 20 mg, 1 / d, for 6 to 12 months; the control group did not give atorvastatin, The same as other treatments. Before and after treatment, hematuria, blood lipid and liver and kidney function were observed, and coronary angiography was performed. Results: 18.3% of the patients in the observation group progressed to coronary artery disease, with 49.4% in the control group and 11.3% in the observation group, which was significantly less than 62.5% in the control group (P <0.05). Lesions and disappearance of lesions although better than the control group, but no statistically significant. The number of lesions improved (lesion lesion disappeared) observation group was significantly more than the control group (P <0.05). Conclusion: Atorvastatin treatment can significantly reduce the recent progression of coronary artery disease and worsen the disease in patients with normal blood lipids.